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GUEST EDITORIAL
An overview in the treatment of advanced ovarian cancer
MRC Gynaecological Cancer Working Party
Ovarian cancer is currently the most common gynaecological
malignancy among women in the UK. About 5,000 patients
are treated each year and 85% of these die as a result of the
disease. Although mortality rates for other gynaecological
cancers have been decreasing, owing in part to an improve-
ment in methods ofearly detection such as cervical screening,
the death rate for ovarian cancer has been increasing, doub-
ling over the past 70 years in England and Wales (Beral,
1987). One major problem with ovarian cancer is that it is
usually asymptomatic in the early stages and consequently
patients often do not present until the later stages of the
disease by which time prognosis is usually very poor. In the
early stages (I-IIa) of the disease 5-year survival rates are in
the region of 50-70%, whereas in advanced stages the cor-
responding survival rates fall to 5-10%.
The most effective first-line treatment for this malignancy
is complete surgical removal of the tumour. Indeed, for stage
I disease, surgery is often the only recommended treatment
and usually consists of total abdominal hysterectomy,
bilateral salpingo-oophorectomy and omentectomy. In other
early stages surgery may be supplemented by radiotherapy or
chemotherapy. For patients in whom disease is more
advanced, debulking of the tumour is favoured since bulk of
tumour remaining after operation has been shown to be an
important prognostic factor (Griffith, 1975). Subsequent
treatment for these cases usually involves the use of some
form of chemotherapy.
Ovarian cancer was one of the first solid malignant
tumours to be treated by cytotoxic chemotherapy, and single
alkylating agents such as cyclophosphamide and melphalan
have been used in therapy for over 30 years. More recently,
there has been an increased tendency to use combinations of
cytotoxic drugs, often including cisplatin, in treatment.
Although there is good evidence that combination
chemotherapy achieves higher response rates than single-
agent chemotherapy (Young et al., 1978), and that cisplatin-
based chemotherapy achieves higher response rates than non-
cisplatin-based chemotherapy, it is not clear that these higher
response rates result in survival advantages.
For example, 39 randomised clinical trials (a full list is
available from the authors), involving approximately 5,000
patients, which have compared first line combination and
single-agent therapy have been identified in the literature. Of
these, only three have reported a statistically significant (at
formal test size 5%) survival advantage for combination
chemotherapy and one has reported the same for single-agent
therapy. The large majority of these randomised trials have
been equivocal and it is therefore hardly surprising that there
is still controversy concerning the relative merits of the two
forms of treatment. The problem is that individual trials have
been relatively small and, since the width of confidence inter-
vals is inversely related to sample size, they have not had the
power to detect moderate but arguably worthwhile survival
differences. For example, assuming a 2-year survival rate of
20% using a single agent, to detect reliably an improvement of
10% in this rate (to 30%) requires 700 patients (with a 5% test
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size and 90% power). To detect reliably a corresponding 5%
increase in 2-year survival rate requires 2,500 patients.
The largest published two-arm trial (Brodovsky, 1984)
involved only 374 patients and most trials have been con-
siderably smaller than this. As a consequence, the distribu-
tion of results from these trials is entirely consistent with the
possibility that a moderate survival benefit of between 5 and
10% exists for combination chemotherapy.
The role of platinum in the treatment of this disease has
been considered in 30 randomised clinical trials. This has
involved a total of approximately 4,500 patients. In this
context, it is appropriate to compare single-agent cisplatin
both with combinations which contain cisplatin and com-
binations which do not; it is also appropriate to compare
non-platinum single agents with combinations containing
cisplatin. These comparisons allow the question of whether
combination chemotherapy has any long-term survival
advantage over single agent chemotherapy to be addressed. A
related question is whether the addition of cisplatin to a
combination confers any survival advantage.
Considerable interest is being shown in the use of carbo-
platin and it has been suggested that it is as effective as
cisplatin but with the advantage of being less toxic. This
claim has been made on the basis of a few trials which have
shown that there is apparently no statistically significant
difference between the two. However, problems of small sam-
ple size also leave this question unresolved.
The question of whether one form of treatments has
moderate but worthwhile advantages cannot be resolved by
literature reviews alone. There are two means of establishing
such moderate degrees of benefit. The first would be to
conduct a randomised clinical trial large enough to detect
these differences. Such a trial would require the accrual of
thousands of patients and could take up to 10 years to
complete. Alternatively, a formal overview could be under-
taken since it is possible that there is sufficient information
already available from previous and current randomised
trials to resolve these issues. In any event, it is clearly sensible
to consider this evidence in depth before embarking on a
large prospective trial.
We therefore propose an overview of all relevant ran-
domised trials as the next step in determining the roles of
different forms of chemotherapy in the treatment of
advanced ovarian cancer. By combining the results of all
relevant randomised trials such an overview can provide a
means ofassessing accurately the survival benefits ofdifferent
forms ofchemotherapy. The British Medical Research Coun-
cil Gynaecological Cancer Working Party has initiated such
an overview for all the treatment comparisons discussed
above. By 1 January 1990 we had identified 53 relevant
studies with a total of nearly 10,000 patients which are
suitable for inclusion into this overview. By this date we had
obtained all individual patient data for 28 of these 53 studies.
Nearly all study investigators have been able to provide us
with unpublished updated follow-up data. This will allow us
to report reliably on the effects on long-term survival, an
end-point on which there is very little comparative inform-
ation.
To avoid publication bias the proposed overview will in-
clude all relevant trials, both published and unpublished,
since there is increasing evidence that both investigators and
journal editors are more likely to publish trials with positive
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results than those with 'negative' results (Simes, 1986; Begg
& Berlin, 1989). Of the 53 relevant studies we have identified,
11 (21%) are unpublished. The identification of all published
and unpublished trials is a major undertaking in itself and we
would be grateful to receive details from any investigator
who has undertaken such a randomised clinical trial and has
not already been contacted personally. Non-randomised trials
will be excluded for the well catalogued reasons of the poten-
tial for bias implicit in such studies (Chalmers et al., 1972).
Although the methodology of overviews has become
popular, it has also been subject to much criticism. Perhaps
the most important is that the results of an overview are
difficult to interpret and emphasise general forms of treat-
ment, rather than describing specific treatments in exact set-
tings. It is true that an overview does not describe specific
treatinents for individual patients. Nevertheless, it does pro-
vide reliable evidence of the overall survival benefits of one
form of treatment over another. Cody and Slevin (1989) have
recently delineated the considerable problems in deciding the
appropriate treatment for patients with advanced ovarian
cancer. The overview would therefore be of considerable
value not only as a basis for future studies, but for the
clinician faced with a patient to treat. The reliability and
stability of the information from such an overview may
prove invaluable when making these treatment decisions.
Overviews also raise important clinical issues by highlighting
different opinions regarding treatment. By initiating interna-
tional collaborative ventures they provide a forum for debate
which can lead to a useful exchange of ideas between trialists
which may then be formulated as protocols for future
studies.
The value of this approach has been demonstrated recently
by the Early Breast Cancer Trialists' Collaborative Group
which has led to the increased use of adjuvant therapy in
patients with this disease. As a result it is estimated that an
additional 1,000 lives per year may be saved in the UK alone
(Early Breast Cancer Trialists' Collaborative Group, 1988;
Editorial, 1989). Similarly, there are about 3,000 cases of
advanced ovarian cancer diagnosed annually so that a 5%
(from 20 to 25%) improvement in the 2-year survival rate
could potentially 'save' 150 of these lives while a 10% im-
provement would save 300. Worldwide these figures mean
that many thousands of deaths would be prevented each
year. This would have a considerable impact on public
health.
The results of this overview will give clinicians a more
complete knowledge of the effects of the treatments they
prescribe. This must be to the ultimate benefit of both
clinician and patient.
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